Product news

Share this article:

Eli Lilly announced that the FDA has approved Cymbalta (duloxetine HCl) for the maintenance treatment of major depressive disorder in adults.

Novartis' Diovan (valsartan), an angiotensin receptor blocker, has been approved following a priority review by the FDA for the treatment of high blood pressure in children and adolescents ages six to 16.

Alcon announced that the FDA has approved Triesence (triamcinolone acetonide injectable suspension) 40 mg/mL, a preservative-free synthetic corticosteroid for visualization during vitrectomy and treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions